These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

291 related items for PubMed ID: 28740376

  • 1. Fluticasone propionate/formoterol for COPD management: a randomized controlled trial.
    Papi A, Dokic D, Tzimas W, Mészáros I, Olech-Cudzik A, Koroknai Z, McAulay K, Mersmann S, Dalvi PS, Overend T.
    Int J Chron Obstruct Pulmon Dis; 2017; 12():1961-1971. PubMed ID: 28740376
    [Abstract] [Full Text] [Related]

  • 2. The EFFECT trial: evaluating exacerbations, biomarkers, and safety outcomes with two dose levels of fluticasone propionate/formoterol in COPD.
    Papi A, Jones PW, Dalvi PS, McAulay K, McIver T, Dissanayake S.
    Int J Chron Obstruct Pulmon Dis; 2015; 10():2431-8. PubMed ID: 26648706
    [Abstract] [Full Text] [Related]

  • 3. Once-daily fluticasone furoate/vilanterol 100/25 mcg versus twice daily combination therapies in COPD - mixed treatment comparisons of clinical efficacy.
    Stynes G, Svedsater H, Wex J, Lettis S, Leather D, Castelnuovo E, Detry M, Berry S.
    Respir Res; 2015 Feb 15; 16(1):25. PubMed ID: 25849223
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and safety of budesonide and formoterol in one pressurized metered-dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6-month randomized clinical trial.
    Tashkin DP, Rennard SI, Martin P, Ramachandran S, Martin UJ, Silkoff PE, Goldman M.
    Drugs; 2008 Feb 15; 68(14):1975-2000. PubMed ID: 18778120
    [Abstract] [Full Text] [Related]

  • 5. Reduction in clinically important deterioration in chronic obstructive pulmonary disease with aclidinium/formoterol.
    Singh D, D'Urzo AD, Chuecos F, Muñoz A, Garcia Gil E.
    Respir Res; 2017 May 30; 18(1):106. PubMed ID: 28558833
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Efficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered-dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1-year randomized controlled clinical trial.
    Rennard SI, Tashkin DP, McElhattan J, Goldman M, Ramachandran S, Martin UJ, Silkoff PE.
    Drugs; 2009 May 30; 69(5):549-65. PubMed ID: 19368417
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and safety of once-daily QVA149 compared with the free combination of once-daily tiotropium plus twice-daily formoterol in patients with moderate-to-severe COPD (QUANTIFY): a randomised, non-inferiority study.
    Buhl R, Gessner C, Schuermann W, Foerster K, Sieder C, Hiltl S, Korn S.
    Thorax; 2015 Apr 30; 70(4):311-9. PubMed ID: 25677679
    [Abstract] [Full Text] [Related]

  • 9. Effects of roflumilast in COPD patients receiving inhaled corticosteroid/long-acting β2-agonist fixed-dose combination: RE(2)SPOND rationale and study design.
    Rennard SI, Martinez FJ, Rabe KF, Sethi S, Pizzichini E, McIvor A, Siddiqui S, Anzueto A, Zhu H.
    Int J Chron Obstruct Pulmon Dis; 2016 Apr 30; 11():1921-8. PubMed ID: 27574416
    [Abstract] [Full Text] [Related]

  • 10. Budesonide/formoterol maintenance and reliever therapy in Asian patients (aged ≥16 years) with asthma: a sub-analysis of the COSMOS study.
    Vogelmeier C, Naya I, Ekelund J.
    Clin Drug Investig; 2012 Jul 01; 32(7):439-49. PubMed ID: 22607479
    [Abstract] [Full Text] [Related]

  • 11. Influence of salmeterol/fluticasone via single versus separate inhalers on exacerbations in severe/very severe COPD.
    Hagedorn C, Kässner F, Banik N, Ntampakas P, Fielder K.
    Respir Med; 2013 Apr 01; 107(4):542-9. PubMed ID: 23337300
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD.
    Zhong N, Wang C, Zhou X, Zhang N, Humphries M, Wang L, Thach C, Patalano F, Banerji D, LANTERN Investigators.
    Int J Chron Obstruct Pulmon Dis; 2015 Apr 01; 10():1015-26. PubMed ID: 26082625
    [Abstract] [Full Text] [Related]

  • 15. The CONCEPT trial: a 1-year, multicenter, randomized,double-blind, double-dummy comparison of a stable dosing regimen of salmeterol/fluticasone propionate with an adjustable maintenance dosing regimen of formoterol/budesonide in adults with persistent asthma.
    FitzGerald JM, Boulet LP, Follows RM.
    Clin Ther; 2005 Apr 01; 27(4):393-406. PubMed ID: 15922813
    [Abstract] [Full Text] [Related]

  • 16. A score to predict short-term risk of COPD exacerbations (SCOPEX).
    Make BJ, Eriksson G, Calverley PM, Jenkins CR, Postma DS, Peterson S, Östlund O, Anzueto A.
    Int J Chron Obstruct Pulmon Dis; 2015 Apr 01; 10():201-9. PubMed ID: 25670896
    [Abstract] [Full Text] [Related]

  • 17. Nebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial.
    Baumgartner RA, Hanania NA, Calhoun WJ, Sahn SA, Sciarappa K, Hanrahan JP.
    Clin Ther; 2007 Feb 01; 29(2):261-78. PubMed ID: 17472819
    [Abstract] [Full Text] [Related]

  • 18. Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Improves Lung Function versus Monotherapies in GOLD Category A Patients with COPD: Pooled Data from the Phase III PINNACLE Studies.
    Martinez FJ, Rabe KF, Lipworth BJ, Arora S, Jenkins M, Martin UJ, Reisner C.
    Int J Chron Obstruct Pulmon Dis; 2020 Feb 01; 15():99-106. PubMed ID: 32021148
    [Abstract] [Full Text] [Related]

  • 19. Glycopyrronium once-daily significantly improves lung function and health status when combined with salmeterol/fluticasone in patients with COPD: the GLISTEN study, a randomised controlled trial.
    Frith PA, Thompson PJ, Ratnavadivel R, Chang CL, Bremner P, Day P, Frenzel C, Kurstjens N, Glisten Study Group.
    Thorax; 2015 Jun 01; 70(6):519-27. PubMed ID: 25841237
    [Abstract] [Full Text] [Related]

  • 20. Efficacy of aclidinium/formoterol 400/12 µg, analyzed by airflow obstruction severity, age, sex, and exacerbation history: pooled analysis of ACLIFORM and AUGMENT.
    D'Urzo AD, Singh D, Donohue JF, Kerwin EM, Ribera A, Molins E, Chuecos F, Jarreta D, Gil EG.
    Int J Chron Obstruct Pulmon Dis; 2019 Jun 01; 14():479-491. PubMed ID: 30880938
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.